4/A: CorMedix Chief Legal Officer Amends SEC Filing After Stock Transaction

CorMedix's Chief Legal Officer, Beth Zelnick Kaufman, amended a previous SEC filing to correct the number of shares owned after a transaction.

Summary

• Beth Zelnick Kaufman, Chief Legal Officer of CorMedix Inc., filed an amendment to a previous SEC Form 4.
• The amendment corrects the number of common stock shares beneficially owned following a transaction on December 12, 2024.
• The original filing incorrectly stated the number of shares and included a duplicate reference to Restricted Stock Units.
• The corrected filing shows that Ms. Kaufman directly owns 43,956 shares of CorMedix common stock after the transaction.
• The transaction involved the disposal of 6,044 shares at a price of $8.77 per share.

Sentiment

Score: 7

Explanation: The document is a routine correction of a previous filing, indicating a neutral sentiment. The correction shows adherence to regulations, which is a positive sign.

Industry Context

This filing is a routine disclosure of stock transactions by a company officer, which is a common practice in publicly traded companies.

Comparison to Industry Standards

• SEC Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders.
• The amendment indicates a correction of a previous filing, which is not uncommon and demonstrates adherence to regulatory requirements.
• The transaction is a relatively small number of shares compared to the overall market capitalization of the company, and is not unusual for a company officer.

Stakeholder Impact

• The amendment provides accurate information to shareholders regarding the beneficial ownership of company stock by its officers.
• The correction ensures transparency and compliance with SEC regulations.

Key Dates

Keywords

SEC Filing, Form 4, CorMedix, CRMD, Beneficial Ownership, Stock Transaction, Chief Legal Officer, Amendment